Recursion Pharmaceuticals Shares Rise Following FDA Alignment on REC-4881 Phase 3 Design

Recursion Pharmaceuticals (RXRX) saw its stock rise nearly 4% after announcing that it has reached alignment with the FDA regarding the Phase 3 clinical trial design for REC-4881. The drug is being developed to treat familial adenomatous polyposis, a condition with no currently approved therapies and an estimated $15 billion market opportunity. The FDA's acceptance of polyp excision as part of the primary endpoint for event-free survival is viewed favorably by investors, as it may prevent the need for longer, more expensive trials. While this regulatory progress is a significant milestone for Recursion's AI-driven drug discovery platform, the Phase 3 trial is not expected to commence until the second half of 2027.

By Josh Kohn-Lindquist · Motley Fool ·

Recursion Pharmaceuticals Shares Rise Following FDA Alignment on REC-4881 Phase 3 Design

Tickers: $RLAY $RXRX $SDGR

Topics: AI drug discovery Familial adenomatous polyposis FDA alignment Phase 3 clinical trial design

Read the full article at Motley Fool

Part of the story Recursion Pharmaceuticals Shares Rise Following FDA Alignment on REC-4881 Phase 3 Design (2 articles)

More World news